Exome sequencing in dementia with Lewy bodies

Translational Psychiatry

Volumn 6, Issue , 2016, Pages

  Keogh, M J ^a   Kurzawa Akanbi, M ^a   Griffin, H ^a   Douroudis, K ^a   Ayers, K L ^a   Hussein, R I ^a   Hudson, G ^a   Pyle, A ^a   Cordell, H J ^a   Attems, J ^b,c   McKeith, I G ^b,c   O'Brien, J T ^b,c   Burn, D J ^b,c   Morris, C M ^b,c   Thomas, A J ^b,c   Chinnery, P F ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; DNA; TAR DNA BINDING PROTEIN;

AGED; ALLELE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CHMP2B GENE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE DURATION; DISEASE PREDISPOSITION; DNA EXTRACTION; EXOME; FAMILY HISTORY; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; PARK2 GENE; PARKINSON DISEASE; PENETRANCE; PSEN2 GENE; SQSTM1 GENE; TDP 43 PROTEINOPATHY; FEMALE; GENETICS; MALE;

AGED; EXOME; FEMALE; HUMANS; LEWY BODY DISEASE; MALE;

EID: 84957578057     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.220     Document Type: Article

References (26)

1. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 2003; 74: 720-724.
2. Bostrom F, Jonsson L, Minthon L, Londos E. Patients with Lewy body dementia use more resources than those with Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 713-719.
3. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
4. Nervi A, Reitz C, Tang MX, Santana V, Piriz A, Reyes D et al. Familial aggregation of dementia with Lewy bodies. Arch Neurol 2011; 68: 90-93.
5. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 2009; 24: 392-400.
6. Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S et al. Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 2009; 66: 578-583.
7. Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014; 23: 6139-6146.
8. Harding AJ, Das A, Kril JJ, Brooks WS, Duffy D, Halliday GM. Identification of families with cortical Lewy body disease. Am J Med Genet B Neuropsychiatr Genet 2004; 128: 118-122.
9. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.
10. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009; 117: 635-652.
11. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
12. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 2003; 62: 1287-1301.
13. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-423.
14. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-127.
15. An XK, Peng R, Li T, Burgunder JM, Wu Y, Chen WJ et al. LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Eur J Neurol 2008; 15: 301-305.
16. Lleo A, Blesa R, Gendre J, Castellvi M, Pastor P, Queralt R et al. A novel presenilin 2 gene mutation (D439A) in a patient with early-onset Alzheimer's disease. Neurology 2001; 57: 1926-1928.
17. Sassi C, Guerreiro R, Gibbs R, Ding J, Lupton MK, Troakes C et al. Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease. Neurobiol Aging 2014; 35: 2881.e1-2881.e6.
18. Parkinson N, Ince PG, Smith MO, Highley R, Skibinski G, Andersen PM et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology 2006; 67: 1074-1077.
19. Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011; 68: 1440-1446.
20. Le Ber I, Camuzat A, Guerreiro R, Bouya-Ahmed K, Bras J, Nicolas G et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol 2013; 70: 1403-1410.
21. Bras J, Simon-Sanchez J, Federoff M, Morgadinho A, Januario C, Ribeiro M et al. Lack of replication of association between GIGYF2 variants and Parkinson disease. Hum Mol Genet 2009; 18: 341-346.
22. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014; 508: 469-476.
23. Leverenz JB, Fishel MA, Peskind ER, Montine TJ, Nochlin D, Steinbart E et al. Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol 2006; 63: 370-376.
24. Tanikawa S, Mori F, Tanji K, Kakita A, Takahashi H, Wakabayashi K. Endosomal sorting related protein CHMP2B is localized in Lewy bodies and glial cytoplasmic inclusions in alpha-synucleinopathy. Neurosci Lett 2012; 527: 16-21.
25. Tanji K, Odagiri S, Miki Y, Maruyama A, Nikaido Y, Mimura J et al. p62 deficiency enhances alpha-synuclein pathology in mice. Brain Pathol 2014; 25: 552-564.
26. Cuyvers E, van der Zee J, Bettens K, Engelborghs S, Vandenbulcke M, Robberecht C et al. Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiol Aging 2015; 36: 2005.e15-2005.e22.